Vaccines and Related Biological Products Advisory Committee; Notice of Meeting, 18910-18911 [2017-08176]
Download as PDF
18910
Federal Register / Vol. 82, No. 77 / Monday, April 24, 2017 / Notices
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: April 18, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation and Analysis.
[FR Doc. 2017–08189 Filed 4–21–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0001]
Safe Use Symposium: A Focus on
Reducing Preventable Harm From
Drugs in the Outpatient Setting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public symposium.
The Food and Drug
Administration’s (FDA or Agency)
Center for Drug Evaluation and
Research, Professional Affairs and
Stakeholder Engagement Staff (PASES),
is hosting a 1-day public symposium
entitled ‘‘Safe Use Symposium: A Focus
on Reducing Preventable Harm From
Drugs in the Outpatient Setting.’’ The
purpose of this symposium is to discuss
sources of preventable harm from drugs
in the outpatient setting and to
stimulate the exchange of ideas among
thought leaders on interventions to
reduce preventable harms and how
these interventions can be studied.
DATES: The public symposium will be
held on June 15, 2017, from 8 a.m. to 4
p.m.
ADDRESSES: The public symposium will
be held at FDA’s White Oak campus,
10903 New Hampshire Ave, Bldg. 31
(The Great Room C), Silver Spring, MD
20903. Entrance for the public
symposium participants (non-FDA
employees) is through Bldg. 1 where
routine security check procedures will
be performed. For parking and security
information, please refer to https://
www.fda.gov/AboutFDA/
WorkingatFDA/BuildingsandFacilities/
WhiteOakCampusInformation/
ucm241740.htm.
FOR FURTHER INFORMATION CONTACT:
Christine Lee, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Silver Spring, MD
20993–0002, 240–402–4228, email:
CDERSafeUseInitiative@fda.hhs.gov.
jstallworth on DSK7TPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
13:48 Apr 21, 2017
Jkt 241001
The Food
and Drug Administration’s (FDA) Center
for Drug Evaluation and Research,
Professional Affairs and Stakeholder
Engagement Staff (PASES), is hosting a
1-day public symposium entitled ‘‘Safe
Use Symposium: A Focus on Reducing
Preventable Harm From Drugs in the
Outpatient Setting.’’ The purpose of this
symposium is to discuss sources of
preventable harm from drugs in the
outpatient setting, such as the use of
inappropriate medications in particular
age groups, drug-drug interactions,
unintended exposures, and misuse; and
to stimulate the exchange of ideas
among thought leaders on interventions
to reduce preventable harms and how
these interventions can be studied. This
information may assist FDA in
identifying significant and unexplored
areas of preventable harm from drugs for
the purpose of funding future research
through the Safe Use Initiative. The
symposium will feature presentations
on sources of outpatient preventable
harms, possible interventions, and
future research topics. Areas to be
discussed include identifying drugs and
populations associated with a higher
risk of preventable harm, as well as
events which may be amenable to
interventions. Methods to measure the
effect of interventions and how to apply
these to the outpatient setting will also
be an important focus of discussion.
Presenters will represent
multidisciplinary backgrounds from
government, academia, patient safety
groups, health care industry, and
clinicians. There will be opportunities
for interaction between speakers and
attendees as well as question and
answer sessions.
Registration: There is no registration
fee to attend the public symposium.
Early registration is recommended
because seating is limited, and
registration will be on a first-come, firstserved basis. There will be no onsite
registration. Persons interested in
attending this symposium must register
online at https://wcms.fda.gov/FDAgov/
Drugs/NewsEvents/
ucm538670.htm?SSContributor=true.
For those without Internet access, please
contact Christine Lee (see FOR FURTHER
INFORMATION CONTACT) to register. If you
need special accommodations due to a
disability, please contact Christine Lee
at least 7 days in advance.
Transcripts: A transcript of the
symposium will be available for review
at the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852, and on the
Internet at https://www.regulations.gov
approximately 30 days after the
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00022
Fmt 4703
Sfmt 4703
symposium. Transcripts will also be
available in either hard copy or on CD–
ROM, after submission of a Freedom of
Information request. The Freedom of
Information office address is available
on the Agency’s Web site at https://
www.fda.gov.
Dated: April 17, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–08182 Filed 4–21–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0001]
Vaccines and Related Biological
Products Advisory Committee; Notice
of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Vaccines and Related
Biological Products Advisory
Committee (VRBPAC). The general
function of the committee is to provide
advice and recommendations to the
Agency on FDA’s regulatory issues. The
meeting will be open to the public.
DATES: The meeting will be held on May
17, 2017, from 8:30 a.m. to 4:45 p.m.
ADDRESSES: FDA White Oak Campus,
10903 New Hampshire Ave., Building
31 Conference Center, the Great Room
(rm. 1503), Silver Spring, MD 20993–
0002. For those unable to attend in
person, the meeting will also be Web
Cast and will be available at the
following link: https://
collaboration.fda.gov/rsvvaccine0517.
Answers to commonly asked questions
including information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm408555.htm.
FOR FURTHER INFORMATION CONTACT:
CAPT Serina Hunter-Thomas or
Rosanna Harvey, Center for Biologics
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 6307C,
Silver Spring, MD 20993–0002, at 240–
402–5771 serina.hunter-thomas@
fda.hhs.gov and 240–402–8072,
rosanna.harvey@fda.hhs.gov, or FDA
SUMMARY:
E:\FR\FM\24APN1.SGM
24APN1
jstallworth on DSK7TPTVN1PROD with NOTICES
Federal Register / Vol. 82, No. 77 / Monday, April 24, 2017 / Notices
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
SUPPLEMENTARY INFORMATION:
Agenda: On May 17, 2017, the
VRBPAC will meet in an open session
to discuss considerations for evaluation
of Respiratory Syncytial Virus vaccine
candidates in seronegative infants. FDA
intends to make background material
available to the public no later than 2
business days before the meeting. If
FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before May 10, 2017. Oral
presentations from the public will be
scheduled between approximately 1:15
p.m. and 2:15 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before May 2,
2017. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by May 3, 2017.
VerDate Sep<11>2014
13:48 Apr 21, 2017
Jkt 241001
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact CAPT Serina
Hunter-Thomas at least 7 days in
advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at:
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: April 18, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–08176 Filed 4–21–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0001]
Science Board to the Food and Drug
Administration Advisory Committee;
Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Science Board to the
FDA. The general function of the
committee is to provide advice to the
Commissioner of Food and Drugs and
other appropriate officials on specific,
complex scientific and technical issues
important to FDA and its mission,
including emerging issues within the
scientific community. Additionally, the
Science Board provides advice to the
Agency on keeping pace with technical
and scientific developments including
in regulatory science, input into the
Agency’s research agenda and on
upgrading its scientific and research
facilities and training opportunities. It
will also provide, where requested,
expert review of Agency sponsored
intramural and extramural scientific
SUMMARY:
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
18911
research programs. This meeting is open
to the public.
DATES: The meeting will be held on May
9, 2017, from 2 p.m. to 5 p.m.
ADDRESSES: FDA White Oak Campus,
10903 New Hampshire Ave, Bldg. 31,
Rm. 1404, Silver Spring, MD 20993.
This meeting will take place via audio
Webcast. To access the link for the
audio Webcast check the Agency’s Web
site at https://www.fda.gov/
AdvisoryCommittees/default.htm and
scroll down to the appropriate advisory
committee meeting link. Answers to
commonly asked questions including
information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm408555.htm.
For those unable to access the audio
Webcast, a conference room with a
speakerphone will be reserved at the
meeting location provided at the top of
the ADDRESSES section. Seating is
limited and is available on a first come,
first served basis.
FOR FURTHER INFORMATION CONTACT:
Rakesh Raghuwanshi, Office of the
Chief Scientist, Office of the
Commissioner, Food and Drug
Administration, 10903 New Hampshire
Ave, Bldg. 1, Rm. 3309, Silver Spring
MD 20993, 301–796–4769,
rakesh.raghuwanshi@fda.hhs.gov, or
FDA Advisory Committee Information
Line, 1–800–741–8138 (301–443–0572
in the Washington, DC area). A notice in
the Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
SUPPLEMENTARY INFORMATION:
Agenda: The Science Board will
provide recommendations on the
Agency’s Innovation Funds work plan
as prescribed in section 1002 of the 21st
Century Cures Act (Pub. L. 114–255).
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
E:\FR\FM\24APN1.SGM
24APN1
Agencies
[Federal Register Volume 82, Number 77 (Monday, April 24, 2017)]
[Notices]
[Pages 18910-18911]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-08176]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-N-0001]
Vaccines and Related Biological Products Advisory Committee;
Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming
public advisory committee meeting of the Vaccines and Related
Biological Products Advisory Committee (VRBPAC). The general function
of the committee is to provide advice and recommendations to the Agency
on FDA's regulatory issues. The meeting will be open to the public.
DATES: The meeting will be held on May 17, 2017, from 8:30 a.m. to 4:45
p.m.
ADDRESSES: FDA White Oak Campus, 10903 New Hampshire Ave., Building 31
Conference Center, the Great Room (rm. 1503), Silver Spring, MD 20993-
0002. For those unable to attend in person, the meeting will also be
Web Cast and will be available at the following link: https://collaboration.fda.gov/rsvvaccine0517. Answers to commonly asked
questions including information regarding special accommodations due to
a disability, visitor parking, and transportation may be accessed at:
https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.
FOR FURTHER INFORMATION CONTACT: CAPT Serina Hunter-Thomas or Rosanna
Harvey, Center for Biologics Evaluation and Research, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 6307C, Silver
Spring, MD 20993-0002, at 240-402-5771 serina.hunter-thomas@fda.hhs.gov
and 240-402-8072, rosanna.harvey@fda.hhs.gov, or FDA
[[Page 18911]]
Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in
the Washington, DC area). A notice in the Federal Register about last
minute modifications that impact a previously announced advisory
committee meeting cannot always be published quickly enough to provide
timely notice. Therefore, you should always check the Agency's Web site
at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to
the appropriate advisory committee meeting link, or call the advisory
committee information line to learn about possible modifications before
coming to the meeting.
SUPPLEMENTARY INFORMATION:
Agenda: On May 17, 2017, the VRBPAC will meet in an open session to
discuss considerations for evaluation of Respiratory Syncytial Virus
vaccine candidates in seronegative infants. FDA intends to make
background material available to the public no later than 2 business
days before the meeting. If FDA is unable to post the background
material on its Web site prior to the meeting, the background material
will be made publicly available at the location of the advisory
committee meeting, and the background material will be posted on FDA's
Web site after the meeting. Background material is available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the
appropriate advisory committee meeting link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before May
10, 2017. Oral presentations from the public will be scheduled between
approximately 1:15 p.m. and 2:15 p.m. Those individuals interested in
making formal oral presentations should notify the contact person and
submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation on or before May 2, 2017. Time allotted for
each presentation may be limited. If the number of registrants
requesting to speak is greater than can be reasonably accommodated
during the scheduled open public hearing session, FDA may conduct a
lottery to determine the speakers for the scheduled open public hearing
session. The contact person will notify interested persons regarding
their request to speak by May 3, 2017.
Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact CAPT Serina Hunter-Thomas at least 7 days in advance of the
meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at: https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: April 18, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-08176 Filed 4-21-17; 8:45 am]
BILLING CODE 4164-01-P